Authors
Shotaro Horonushi, Masashi Kudo, Yukiko Sasahara, Jun Ohara, Motokazu Sugimoto, Shin Kobayashi, Hiroto Katoh, Shingo Sakashita, Genichiro Ishii, Naoto Gotohda
Published in
Human pathology. Pages 106303. Nov 07, 2026. Epub Nov 07, 2026.
Abstract
Tumor budding and poorly differentiated clusters (PDCs) have been reported to have prognostic value in various malignancies. However, their relevance in primary duodenal adenocarcinoma remains unclear. This study evaluated the prognostic significance and interobserver agreement of tumor budding and PDCs in patients with pT1b or more advanced primary duodenal adenocarcinoma who underwent endoscopic or surgical resection between 2005 and 2023. Tumor budding and PDCs were assessed by three observers on hematoxylin and eosin-stained sections, classified as low (<5) or high (≥5), and designated as BD-low or BD-high and PDC-low or PDC-high, respectively. Among the 46 patients analyzed, the interobserver agreement was substantial for tumor budding (κ=0.65, 95% confidence interval [CI] 0.47-0.82) and moderate for PDCs (κ=0.48, 95% CI 0.27-0.65). BD-high and PDC-high were associated with adverse pathological features, including larger tumor size, advanced pathological T and N stages, and lymphatic permeation. BD-high was associated with lower recurrence-free survival (RFS; P=0.013) and overall survival (OS; P=0.004), whereas PDC-high was associated with lower RFS (P=0.022) and OS (P=0.045). Tumor budding and PDCs were associated with adverse pathological features and poorer survival outcomes, with acceptable interobserver reproducibility. Our findings support the clinical applicability of tumor budding and PDC assessment for pathological risk stratification in primary duodenal adenocarcinoma.
PMID:
42998686
Bibliographic data and abstract were imported from PubMed on 08 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 4
- Comments 0